439 related articles for article (PubMed ID: 18469549)
1. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
Nielsen VG
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549
[TBL] [Abstract][Full Text] [Related]
2. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
Nielsen VG; Steenwyk BL; Gurley WQ
J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
[TBL] [Abstract][Full Text] [Related]
3. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma.
Nielsen VG; Ellis TC
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):29-33. PubMed ID: 17179823
[TBL] [Abstract][Full Text] [Related]
4. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
5. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
6. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation.
Nielsen VG
Ann Thorac Surg; 2006 May; 81(5):1720-7. PubMed ID: 16631662
[TBL] [Abstract][Full Text] [Related]
7. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.
Nielsen VG
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):191-6. PubMed ID: 19657316
[TBL] [Abstract][Full Text] [Related]
8. Carbon monoxide releasing molecule-2 enhances coagulation and diminishes fibrinolytic vulnerability in subjects exposed to warfarin.
Nielsen VG; Khan ES; Kirklin JK; George JF
Thromb Res; 2010 Jul; 126(1):68-73. PubMed ID: 20406708
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
10. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
Nielsen VG; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
[TBL] [Abstract][Full Text] [Related]
11. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions.
Nielsen VG
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):647-56. PubMed ID: 17890952
[TBL] [Abstract][Full Text] [Related]
13. A new euglobulin clot lysis assay for global fibrinolysis.
Smith AA; Jacobson LJ; Miller BI; Hathaway WE; Manco-Johnson MJ
Thromb Res; 2003; 112(5-6):329-37. PubMed ID: 15041279
[TBL] [Abstract][Full Text] [Related]
14. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
Nielsen VG; Kirklin JK
Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease.
Fujimoto H; Gabazza EC; Hataji O; Yuda H; D'Alessandro-Gabazza CN; Nakano M; Franco OE; Hayashi T; Suzuki K; Adachi Y; Taguchi O
Am J Respir Crit Care Med; 2003 Jun; 167(12):1687-94. PubMed ID: 12615624
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
[TBL] [Abstract][Full Text] [Related]
17. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation.
Nielsen VG; Cohen BM; Cohen E
Blood Coagul Fibrinolysis; 2006 Jan; 17(1):75-81. PubMed ID: 16607085
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
Bouma BN; Mosnier LO
Ann Med; 2006; 38(6):378-88. PubMed ID: 17008302
[TBL] [Abstract][Full Text] [Related]
19. Blood coagulation activation and fibrinolysis during a downhill marathon run.
Sumann G; Fries D; Griesmacher A; Falkensammer G; Klingler A; Koller A; Streif W; Greie S; Schobersberger B; Schobersberger W
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):435-40. PubMed ID: 17581317
[TBL] [Abstract][Full Text] [Related]
20. Clot lifespan model analysis of the effects of warfarin on thrombus growth and fibrinolysis: role of contact protein and tissue factor initiation.
Nielsen VG; Kirklin JK; Holman WL; Steenwyk BL
ASAIO J; 2009; 55(1):33-40. PubMed ID: 19092656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
